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ABSTRACT
Active infective endocarditis is a devastating
disease with high morbidity and mortality,
which generally needs surgery and appropriate
antimicrobial therapy. Selecting an adequate
valve prosthesis is a central issue during surgery.
This editorial discusses the recent literature
available on this important topic.
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SURGICAL OPTIONS
Active infective endocarditis (AIE) is a
devastating disease with high morbidity and
mortality. In general, surgery is a fundamental
part of AIE therapy along with administering an
appropriate antimicrobial therapy. For decades,
morbidity and mortality in surgically treated AIE
has not changed, although surgical methods
have steadily become more sophisticated. Several
risk factors to predict hospital mortality have
been identified. In general, patient morbidity
and mortality depends on the specific type of
microbe involved and the impact on tissue
destruction, multiple resistances to antibiotic
therapy, and the timing of appropriate
antibiotic therapy administration. Clear
differences need to be made between native
and prosthetic valve AIE, since mortality in the
latter group is much higher compared with
native valve AIE. This is due to the formation
of biofilms in prosthetic heart valves, which are
more resistant against antimicrobial therapy and
therefore more easy to develop. Healthy native
valves, however, have an intact endothelium
which prohibits the development of biofilms.
Finally, the existence of previous embolisms,
either central or peripheral, will have a
significant impact on patient outcome. Our
group found in a multivariate analysis that
female gender, sepsis with cardiogenic shock,
and preoperative embolisms are predictors for
hospital mortality [1]. Surgical therapy options
to treat AIE are similar to those used in the
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treatment of valve degeneration. The underlying
principle is to limit foreigner tissue or material as
much as possible in AIE surgical treatment.
Therefore, the primary goal during AIE surgical
valve therapy is to perform valve-sparing
procedures. Preservation of the involved valve
is crucial and generally possible if AIE is limited
to the valve leaflets. Different reconstruction
techniques are available, such as partial or total
leaflet excision with leaflet reconstruction,
followed by the use of an allo- or xenogenic
patch material. Therefore, complete excision of
the macroscopically visualized infected tissue
needs to be carried out. This will overcome the
persistence of AIE, which eventually could
contaminate the foreigner material used during
surgery, leading to the development of a new
biofilm. If the valve annulus or the infection is
extended to the surrounding tissue, then valve
replacement needs to be considered. In
extremely severe cases where extensive cardiac
tissue is involved in combination with multi-
valve involvement, and there is no longer a
possibility to fix a heart valve prosthesis
adequately, then cardiac transplantation is the
only option left. This therapy option, however,
needs to be considered very carefully, since
immunosuppressive medication needs to be
administered in primary septic patients. Also,
the timing of therapy is difficult, and until an
appropriate organ is available for the patient,
bridging is required. For all AIE treatment, the
key point to treatment is that this specific disease
needs to be treated interdisciplinary. Adequate
antibiotic therapy should support the surgical
treatment, of which the effectiveness can be
reflected by the control of clinical parameters,
using echocardiographic follow-up, blood
cultures, and laboratory examination.
For the treatment of sepsis we know ‘‘the
Tarragona strategy’’, which means ‘‘Hit hard and
early’’, with an appropriate antimicrobial
therapy is a crucial treatment strategy. This
should also be the strategy in the surgical
treatment of AIE, by early and complete
debridement of the infective valve tissue,
eventually including the surrounding tissue.
But this raises the question ‘‘What will be the
adequate valve prosthesis in AIE?’’. In general,
heart valve prostheses can be divided into
mechanical and biological origin, and the
choice will be based on age, life expectancy,
co-morbidities and compliance with
anticoagulation. The only available guidelines
for appropriate selection of valve prosthesis for
the surgical treatment of AIE are performed by
Byrne et al. [2]. Unfortunately, the information
given on accurate elected valve prosthesis is not
specific for AIE treatment, although the same
criteria for valve replacement due to
degeneration are used. Again the choice of
prosthesis was recommend to be based on a
patient’s age, life expectancy, co-morbidities
and compliance with anticoagulation. This
important recommendation in choosing the
correct and most optimal valve prosthesis is
supported on Class IIa, level of evidence B or
Class IIb, level of evidence B analyses [1]. When
evaluating the studies on which these
recommendations are based, it is important to
know that the most recent paper was published
in 2002 [1]. Also, the patient cohorts are on
average only a limited number, between a
minimum of 41 and a maximum of 221
patients. This makes it difficult to find
statistically significant differences between
groups. In the case of a patient suffering from
either native valve or prosthetic valve
endocarditis with periannular abscess, it has
been indicated that the use of a homograft may
be reasonable [1]. Today, it is well accepted that
homografts have the most resistance against
infection. This has been demonstrated in
vascular prosthetic graft infection, where using
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a vascular allograft implantation leads to the
highest cure rates of prosthetic infections [3]. In
general, in cardiac surgery, younger patients
receive mechanical heart valves and older
patients get a stented or stentless bioprosthesis
implanted. The highly diseased younger
patients receive cryopreserved allograft. The
reason for this is that allografts are rare and
therefore generally reserved for younger
patients. It would be of great interest to get
randomized studies with narrow confidence
interval or systemic reviews of RCTs to
investigate the impact of different available




It is difficult to compare different valve prostheses
usedduringAIE sincedifferentpatientpopulations
usually receive different valve prostheses; for
example, in my practice I prefer the use of
cryopreserved allografts for the most severe cases.
Following cardiopulmonary bypass, the time to
allograft should be as short as possible to reduce
additional complications. Therefore, one needs to
determine the correct valve annulus prior to
surgery as the thawing procedure of
cryopreserved allografts is time consuming and
delicate. Patients with less complicated AIE receive
a stented biological heart valve and in the cases
where no cryopreserved allograft is available, a
stentless bioprosthesis is used. In general, stented
biological heart valve prostheses have a good
prognosis; however, these patients generally
suffer from localized AIE without embolism.
Patients receiving a stentless valve are at higher
risk of mortality and morbidity in comparison,
although these patients usually have a more
extended diseased endocarditis compared to
patients who receive mechanical valve
prostheses. Therefore, it is difficult to make
comparisons between the different valve
prostheses. Differences in patient age and valve
recommendation also make it difficult to compare
the different valve prostheses as younger patients,
who are at a lower risk of mortality compared to
older patients due to age, are more likely to receive
a mechanical valve rather than older patients.
Personally I do not favour the use of a mechanical
heart valve even in young patients with AIE if
cerebral embolization is diagnosed, as a fulminate
bleeding during permanent anticoagulation can
occur. It is an extremely difficult and complex
disease and treatment needs to be individually
planned for each patient taking into consideration
the advantages and disadvantages. Delahaye
performed a systemic review about the benefit of
early surgery in infective endocarditis [4]. The
analysis of the literature suggests that early surgery
is favorable for long-term survival; however,
cardiologist does also see many patients,
especially with native valve endocarditis that can
be cured without surgery. This is of course difficult
for a surgeon to mention, but it shows again the
complexity of this devastating disease that always
needs an interdisciplinary team to make the
correct decision for each individual patient. If
surgery is needed, guidelines are available for the
optimal timing [5].
Since the morbidity and mortality has not
been changed over decades in AIE surgery, RCTs
in combination with real world data could be a
point of interest to decrease these rates. Every
effort needs to be undertaken to reduce high
morbidity and mortality due to AIE.
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